Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Zhongguo Zhong Yao Za Zhi ; 48(22): 6234-6248, 2023 Nov.
Artigo em Chinês | MEDLINE | ID: mdl-38114230

RESUMO

Bungarus Parvus, a precious animal Chinese medicinal material used in clinical practice, is believed to be first recorded in Ying Pian Xin Can published in 1936. This study was carried out to analyze the names, geographical distribution, morphological characteristics, ecological habits, poisonousness, and medicinal parts by consulting ancient Chinese medical books and local chronicles, Chinese Pharmacopeia, different processing standards of trditional Chinese medicine(TCM) decoction pieces, and modern literatures. The results showed that the earliest medicinal record of Bungarus Parvus was traced to 1894. In 1930, this medicinal material was used in the formulation of Annao Pills. The original animal, Bungarus multicinctus, was recorded by the name of "Bojijia" in 1521. The morphological characteristics, ecological habits, and poisonousness of the original animal are the same in ancient and modern records. The geographical distribution is similar between the ancient records and modern documents such as China Medicinal Animal Fauna. The dried body of young B. multicinctus is used as Bungarus Parvus, which lack detailed references. As a matter of fact, it is still inconclusive whether there are differences between young snakes and adult snakes in terms of active ingredients, pharmacological effects, and clinical applications. This study clarified the medicinal history and present situation of Bungarus Parvus. On the basis of the results, it is suggested that systematic comparison on young and adult B. multicinctus should be carried out to provide references for revising the medicinal parts of B. multicinctus.


Assuntos
Bungarus , Medicamentos de Ervas Chinesas , Animais , Serpentes , China , Medicina Tradicional Chinesa
2.
Artigo em Inglês | MEDLINE | ID: mdl-34497658

RESUMO

BACKGROUND: Luofushan-Baicao Oil (LBO) is an essential oil-rich traditional Chinese medicine (TCM) formula that is commonly used to treat cold, cough, headache, sore throat, swelling, and pain. However, the anti-influenza activities of LBO and the underlying mechanism remain to be investigated. METHODS: The in vitro anti-influenza activity of LBO was tested with methyl thiazolyl tetrazolium (MTT) and plaque assays. The effects of LBO on the expressions of viral nucleoprotein and cytokines were evaluated. In the polyinosinic-polycytidylic acid- (Poly I: C-) induced inflammation model, the influences of LBO on the expression of cytokines and the activation of NF-κB P65 (P65) and interferon regulatory factor 3 (IRF3) were tested. After influenza A virus (IVA) infection, mice were administered with LBO for 5 days. The lung index, histopathologic change, the expression of viral protein, P65, and IRF3 in the lung tissue were measured. The levels of proinflammatory cytokines in serum were examined. RESULTS: In vitro, LBO could significantly inhibit the infection of IVA, decrease the formation of plaques, and reduce the expression of viral nucleoprotein and cytokines. LBO could also effectively downregulate the expression of interleukin-1ß (IL-1ß), interleukin-6 (IL-6), and interferon-ß and the activation of P65 and IRF3 in Poly I:C-treated cells. In the IVA-infected mice model, inhalation of LBO with atomizer could decrease the lung index, alleviate the pathological injury in the lung tissue, and reduce the serum levels of IL-1ß and IL-6. LBO could significantly downregulate the expression of viral protein (nucleoprotein, PB2, and matrix 2 ion channel) and the phosphorylation of P65 and IRF3 in the lungs of mice. CONCLUSION: The therapeutic effects of LBO on treating influenza might result from the regulation of the immune response of IVA infection. LBO can be developed as an alternative therapeutic agent for influenza prevention.

3.
Zhongguo Zhong Yao Za Zhi ; 33(7): 854-9, 2008 Apr.
Artigo em Chinês | MEDLINE | ID: mdl-18589794

RESUMO

There are 63 species Melastomataceae plants in 17 genus, which widely distribute along Yangtze River and the south of China ranging from Tibet autonomous region to Taiwan province. They used as herb medicine in China. A large part of the Melastomataceae plants have bitter, pungent and sweet taste. The meridian distribution of them is liver, spleen and stomach, they have many functions such as "cure rheumatism", "clear heat" and "detoxication", "regulate the flow of qi and alleviate pain", "diuresis and detumescence", "activate the blood and eliminate stasis". Melastomataceae plants not only have exact medical value, but also have abundant resource. So it has very bright perspective of exploitation and utilization.


Assuntos
Medicamentos de Ervas Chinesas/farmacologia , Melastomataceae , Adulto , Criança , China , Medicamentos de Ervas Chinesas/uso terapêutico , Feminino , Humanos , Masculino , Melastomataceae/química , Melastomataceae/classificação , Fitoterapia , Gravidez
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...